> ## Content Index
> Fetch the complete content index at: https://www.industrialbriefs.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biolevate Secures €30M for AI Expansion into U.S. Life Sciences Market
- URL: https://www.industrialbriefs.com/biolevate-ai-expansion-us-life-sciences/
- Published: 2026-09-27T19:00:27.000Z
- Updated: 2026-09-27T19:00:47.000Z
- Description: Biolevate's €30 million Series A funding, led by RAISE France and Orange Ventures, supports its expansion into the U.S., offering AI automation solutions for the life sciences industry.
- Author: IndustrialBriefs
- Tags: ai, policy, government, #enriched

![IB_KEY_FACTS:[{"stat":"€30 million","label":"**Funding Secured**","sublabel":"Biolevate raises €30 million in Series A led by RAISE France and Orange Ventures."},{"stat":"20-fold increase","label":"**Revenue Growth**","sublabel":"Biolevate's annual recurring revenue surged 20-fold in the past year."},{"stat":"80% efficiency","label":"**Regulatory Efficiency**","sublabel":"Biolevate's platform claims to improve regulatory compliance activities by 80%."}]](https://industrial-briefs.ghost.io/favicon.ico)

Biolevate, the Paris-based innovator in AI-powered automation for the life sciences industry, has secured €30 million in a Series A funding round led by RAISE France and Orange Ventures. This significant investment, which also saw participation from MSD Global Health Innovation Fund, Station F, and EQT Ventures, marks a pivotal step in Biolevate's strategic expansion into the United States, with the establishment of a new office in Boston.

**What Happened**  
Biolevate's latest funding round follows a successful €6 million seed round in November 2024 and comes on the heels of impressive commercial growth, with the company reporting a 20-fold increase in annual recurring revenue over the past year. The company, founded by former Dataiku engineers and AI researchers, specializes in developing software that automates complex scientific and regulatory processes. Biolevate's platform integrates artificial intelligence with scientific and regulatory knowledge, creating workflows that maintain the necessary traceability and oversight for heavily regulated environments.

The platform's applications span the life sciences value chain, including scientific research, clinical trials, drug discovery, and regulatory dossier preparation. Biolevate's technology is designed to address bottlenecks in the pharmaceutical industry, where manual processes like literature reviews, regulatory submissions, and compliance activities often slow down product development and market entry. By automating these tasks, Biolevate aims to reduce the administrative burden and accelerate drug discovery and commercialization.

**What This Means for Your Business**  
For AECM professionals and government contractors, Biolevate's expansion into the U.S. signifies a growing opportunity to integrate advanced AI solutions into life sciences operations. The company's platform promises substantial efficiency improvements—up to 80% in regulatory intelligence and compliance activities—which can translate to significant cost savings and faster time-to-market for new therapies. This technological advancement offers an attractive proposition for U.S. companies looking to streamline operations and enhance compliance with regulatory standards, potentially improving their competitive positioning and return on investment.

Furthermore, Biolevate’s presence in Boston, a hub for life sciences and biotech, could foster new partnerships and collaborations with U.S.-based organizations. The expansion signals a broader trend of European tech firms establishing footholds in the American market, which could lead to increased competition and innovation within the industry.

**What US Operators Should Watch**  
U.S. operators in the life sciences and related sectors should keep a close eye on the developments surrounding Biolevate's Boston office. Key timelines to monitor include the deployment of Biolevate’s AI platform across new U.S. clients and any subsequent [regulatory compliance audits](https://www.industrialbriefs.com/autodesk-maintainx-proptech-expansion/) that may arise from its use. Additionally, procurement directors and compliance officers should assess how Biolevate's solutions align with current regulatory frameworks, including forthcoming updates to compliance standards like CMMC and NIST, to ensure seamless integration into existing operations.

*Source: https://pulse2.com/biolevate-raises-e30-million-series-a-led-by-raise-france-and-orange-ventures-expands-into-boston/.* [*Read the original story ->*](https://pulse2.com/biolevate-raises-e30-million-series-a-led-by-raise-france-and-orange-ventures-expands-into-boston/?ref=industrialbriefs.com)

> **Partner Insight** · [VisioneerIT](https://www.visioneerit.com/?ref=industrialbriefs.com)  
>  
> Biolevate's advancements in AI-powered automation highlight the increasing importance of integrating technology into regulated industries. VisioneerIT specializes in modernizing legacy systems and developing enterprise-grade software that can enhance operational efficiency and compliance.  
>  
> [Explore VisioneerIT Cybersecurity →](https://www.visioneerit.com/?ref=industrialbriefs.com)